protein kinase c pkc inhibition a promise not yet
play

Protein Kinase C- ( PKC- ) Inhibition: A Promise not yet Fulfilled Ruboxistaurin, an oral PKC- , was withdrawn on March 15, 2007 by Eli Lilly Dual Inhibition of Classical Protein Kinase C- and Protein Kinase C- Isoforms Protects

0 downloads 2 Views 516 KB Size Report
  1. Protein Kinase C- β ( PKC- β ) Inhibition: A Promise not yet Fulfilled Ruboxistaurin, an oral PKC- β, was withdrawn on March 15, 2007 by Eli Lilly

  2. Dual Inhibition of Classical Protein Kinase C- α and Protein Kinase C- β Isoforms Protects Against Diabetic Nephropathy Diabetes 2013;62:1010-1011

  3. ASCEND Trial: Endothelin Receptor Antagonist Avosentan Significantly Decreased Albuminuria Terminated due to increased CHF and deaths J Am Soc Nephrol 2010;21:527–535

  4. Addition of Atrasentan, an Endothelin Receptor Antagonist, to RAS Blockade Reduces Albuminuria in Diabetic Nephropathy Baseline UACR ~400 mg/g CR J Am Soc Nephrol 2011;22:763-772

  5. Atrasentan Restores Endothelial Glycocalyx Thickness Diabetes 2016;65:2429-2439

  6. Pirfenidone, an Inhibitor of TGF- β at 1200 mg/d, but NOT 2400 mg/d, Improves eGFR from Baseline Pirfenidone (Esbriet) approved to treat idiopathic pulmonary fibrosis J Am Soc Nephrol 2011;22:1144–1151

  7. Pentoxifylline-Lower Decline in eGFR and Greater UAE Reduction Baseline UAE ~1000 mg/day J Am Soc Nephrol 2015;26:220–229

  8. CCX140-B (CCR2 Antagonist) Lowers Albuminuria in Patients with Type 2 DM Monocyte chemoattractant protein-1 (MCP-1), also called C-C chemokine receptor 2 (CCR2) Baseline UAE 400 mg/day Lancet Diabetes & Endo 2015;3:687-696

  9. Pyridoxamine (Pyridorin), a Derivative of Vitamin B6, Inhibits the Formation of Advanced Glycation Endproducts I.V. form of Pyridorin for use in hospital-acquired acute kidney injury Nephron 2015;129:22–28

  10. Finerenone, a 3 rd Generation Nonsteroidal Mineralocorticoid Receptor Antagonists Lowers Albuminuria Baseline UACR ~200 mg/g CR JAMA 2015;314:884-894

  11. Patiromer (Veltassa)— Twice Daily Lowered Potassium Levels FDA Approved on October 22, 2015 but with a Black Box Warning N Engl J Med 2015;372:211-221

  12. Sodium Zirconium Cyclosilicate (ZS-9) 3X Daily X2 days ↓ Hyperkalemia AstraZeneca receives Complete Response Letter from FDA May 27, 2016 JAMA 2014;312:2223-2233

  13. Metformin Improves Whole-Body Glycocalyx Barrier Properties Cardiovasc Diabetol 2013;12:175

Recommend Documents


inhibition of fyn kinase for disease modifying therapy of
Inhibition of Fyn Kinase for Disease-

Inhibition of Fyn Kinase for Disease- Modifying Therapy of Alzheimers Disease

abietane diterpenoids from plectranthus spp as a
Abietane Diterpenoids from Plectranthus

Abietane Diterpenoids from Plectranthus spp. as a potential new class of

new insights into covalent enzyme inhibition
New Insights into Covalent Enzyme

New Insights into Covalent Enzyme Inhibition Application to Anti-Cancer Drug

progress on the co crystallization
Progress on the co-crystallization of

Progress on the co-crystallization of Thermoplasma acidophilum nucleoside

human protein kinase ck2
human protein kinase CK2 Christian

Click chemistry for advanced drug discovery applications of human protein

prediction of human protein kinase substrate specificities
Prediction of Human Protein Kinase

Prediction of Human Protein Kinase Substrate Specificities Javad Safaei 1 ,

pierce promise pierce promise pierce promise pierce
PIERCE PROMISE PIERCE PROMISE

Pierce College Promise PIERCE PROMISE PIERCE PROMISE PIERCE PROMISE

elucidating cell to cell variability in phosphorylation
Elucidating cell-to-cell variability in

Elucidating cell-to-cell variability in phosphorylation of the ERK MAP kinase

1
1 Excitatory Inhibitory excitation

1 Excitatory Inhibitory excitation inhibition 2 excitation excitation

protein kinase c modulates wnt signaling in colon tumoral
Protein Kinase C Modulates Wnt

Protein Kinase C Modulates Wnt Signaling In Colon Tumoral Cell Lines Dra

targeting p2x3 to treat chronic cough
TARGETING P2X3 TO TREAT CHRONIC COUGH

BLU-5937: A Highly Selective P2X3 Homotrimeric Receptor Antagonist, Exhibits

a small molecule glycomime c antagonist of e selec n and
A small molecule glycomime.c

A small molecule glycomime.c antagonist of E-selec.n and CXCR4

ccr5 antagonist ccr5 antagonist drug development issues
CCR5 Antagonist CCR5 Antagonist Drug

CCR5 Antagonist CCR5 Antagonist Drug Development Issues Drug Development

criteria for evaluating a group literary presentation
Criteria for Evaluating a Group

Criteria for Evaluating a Group Literary Presentation SCC Department of English

steve jobs
Steve Jobs Carmine Gallo Columnist,

The Presentation Secrets of Steve Jobs Carmine Gallo Columnist,

naloxone in high schools purpose of this presentation
Naloxone in High Schools Purpose of

Naloxone in High Schools Purpose of this Presentation Educate High School

affimer fimer biother therapeut apeutics ics th the precl
Affimer fimer Biother therapeut

Affimer fimer Biother therapeut apeutics: ics: Th The precl eclinical

steve jobs table of contents
Steve Jobs Table of Contents Steve

The Presentation Genius of Steve Jobs Table of Contents Steve Jobs

hif 2 hif 2 knock out inhibits tumor growth 1 2 arnt pvhl
HIF 2 HIF 2 knock out inhibits

5/4/2016 Disclosure Information PT2385: HIF 2 Antagonist for the Treatment

disclosure
DISCLOSURE No disclosures, financial,

DISCLOSURE No disclosures, financial, or otherwise to declare ANATOMY

reduces fasting and postprandial glucose in a
Reduces Fasting and Postprandial

The Glucagon Receptor Antagonist LGD-6972 Reduces Fasting and Postprandial

apixaban vs vka and aspirin vs placebo in patients with
Apixaban vs VKA and Aspirin vs Placebo

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation